Last reviewed · How we verify
Russian Academy of Medical Sciences — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Mucofalk | Mucofalk | marketed | Other | |||
| Resveratrol Pill | Resveratrol Pill | marketed | Natural polyphenol / Sirtuin activator | SIRT1, antioxidant pathways, NF-κB | Cardiovascular, Metabolic health, Anti-aging | |
| cyclosporine or tacrolimus | cyclosporine or tacrolimus | marketed | Calcineurin inhibitor | Calcineurin (protein phosphatase 2B) | Immunology |
Therapeutic area mix
- Cardiovascular, Metabolic health, Anti-aging · 1
- Immunology · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Albert Einstein Healthcare Network · 1 shared drug class
- Allergan · 1 shared drug class
- Andrew B Adams · 1 shared drug class
- Armando Torres Ramírez · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Astellas Pharma China, Inc. · 1 shared drug class
- Astellas Pharma Europe Ltd. · 1 shared drug class
- Al-Azhar University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Russian Academy of Medical Sciences:
- Russian Academy of Medical Sciences pipeline updates — RSS
- Russian Academy of Medical Sciences pipeline updates — Atom
- Russian Academy of Medical Sciences pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Russian Academy of Medical Sciences — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/russian-academy-of-medical-sciences. Accessed 2026-05-18.